Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue...

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...

Recombinant Vaccines Market to Cross USD 21.46 Billion by 2030 Owing to Technological Advancements in Vaccine Development | Research by SNS Insider Pune, Oct. 03, 2023 (GLOBE NEWSWIRE) -- “The SNS Insider report states that the Recombinant Vaccines Market reached USD 9.18 billion in 2022 and is projected to attain USD 21.46 billion by 2030,...

Shingles Vaccine Market Size, Share, Industry Analysis 2022: Grew at a CAGR of 11.5% and Projected Valuation of US$ 14.1 Bn by 2032 – Persistence Market Research New York, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Global Shingles Vaccine Market was valued at US$ 3.5 Bn in 2021 and is expected to reach US$ 14.1 Bn by 2032 finds Persistence Market Research in a recent...